← Holders
PSP Research LLC
What PSP Research LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2106939 · Filed Oct 21, 2026
- Positions
- 44
- Reported value
- $145.8M
- Opened
- 1
- Closed
- 32
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Dec 31, 2025$114.4M85 positions
- Mar 31, 2026$141.3M79 positions
- Jun 30, 2026$187.9M75 positions
- Sep 30, 2026$145.8M44 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
ISHARES TR0-3 MTH TREASURY | 700K | ±0% | $70.5M | 48.3% |
SPDR SERIES TRUSTST STR SP BIOT | 386.5K | −32.2% | $60.9M | 41.8% |
SERASera Prognostics, Inc. | 2.4M | New | $5M | 3.4% |
HALOHalozyme Therapeutics, Inc. | 3K | −57.1% | $331.2K | 0.2% |
MDGLMadrigal Pharmaceuticals, Inc. | 600 | ±0% | $302.4K | 0.2% |
EXELExelixis, Inc. | 5K | −37.5% | $292.1K | 0.2% |
RPRXRoyalty Pharma plc | 5K | −54.5% | $291.8K | 0.2% |
ARGXArgenx SE | 300 | −53.2% | $287.7K | 0.2% |
NRIXNurix Therapeutics, Inc. | 12K | −52.0% | $284.5K | 0.2% |
TGTXTG Therapeutics, Inc. | 5K | −50.0% | $278.9K | 0.2% |
TARSTarsus Pharmaceuticals, Inc. | 3.5K | −50.0% | $275.1K | 0.2% |
HRMYHarmony Biosciences Holdings, Inc. | 7K | −30.0% | $274.8K | 0.2% |
ARQTArcutis Biotherapeutics, Inc. | 10K | −49.2% | $264.3K | 0.2% |
KNSAKiniksa Pharmaceuticals International, plc | 3.5K | −30.0% | $261.1K | 0.2% |
SUPNSupernus Pharmaceuticals, Inc. | 6K | ±0% | $258.2K | 0.2% |
IMNMImmunome Inc. | 12K | −33.3% | $258.1K | 0.2% |
NBIXNeurocrine Biosciences Inc | 1.8K | −40.0% | $255.3K | 0.2% |
ORKAOruka Therapeutics, Inc. | 3K | ±0% | $249.9K | 0.2% |
TNGXTango Therapeutics, Inc. | 10K | ±0% | $249.5K | 0.2% |
DFTXDefinium Therapeutics, Inc. | 6.5K | −35.0% | $247.4K | 0.2% |
RVMDRevolution Medicines, Inc. | 1.2K | ±0% | $246.3K | 0.2% |
ALKSAlkermes plc. | 6K | ±0% | $243.1K | 0.2% |
AUPHAurinia Pharmaceuticals Inc. | 15K | −50.0% | $242.9K | 0.2% |
INCYIncyte Corp | 2K | −62.3% | $242.7K | 0.2% |
NTLAIntellia Therapeutics, Inc. | 20K | ±0% | $241.2K | 0.2% |
IMVTImmunovant, Inc. | 7K | −46.2% | $236.5K | 0.2% |
STOKStoke Therapeutics, Inc. | 9K | −25.0% | $234K | 0.2% |
KRYSKrystal Biotech, Inc. | 692 | ±0% | $230.1K | 0.2% |
ASNDAscendis Pharma A/S | 1K | −33.3% | $227.8K | 0.2% |
SNDXSyndax Pharmaceuticals Inc | 12K | −40.0% | $225.6K | 0.2% |
KYMRKymera Therapeutics, Inc. | 2K | −50.0% | $223.6K | 0.2% |
DNTHDianthus Therapeutics, Inc. | 2.5K | ±0% | $220.1K | 0.2% |
TRVITrevi Therapeutics, Inc. | 15K | −50.0% | $214.8K | 0.1% |
MIRMMirum Pharmaceuticals, Inc. | 2.5K | ±0% | $213.7K | 0.1% |
IMCRImmunocore Holdings plc | 7K | −53.8% | $212K | 0.1% |
PTGXProtagonist Therapeutics, Inc | 1.5K | −50.0% | $211.3K | 0.1% |
EWTXEdgewise Therapeutics, Inc. | 5K | ±0% | $203K | 0.1% |
ORICOric Pharmaceuticals, Inc. | 13K | ±0% | $175.1K | 0.1% |
DYNDyne Therapeutics, Inc. | 10K | −50.0% | $161.1K | 0.1% |
CMPSCOMPASS Pathways plc | 10K | −44.4% | $124.4K | 0.1% |
OCULOcular Therapeutix, Inc | 15K | ±0% | $115.1K | 0.1% |
CTMXCytomX Therapeutics, Inc. | 39.4K | ±0% | $107.2K | 0.1% |
ARDXArdelyx, Inc. | 30K | −50.0% | $102.6K | 0.1% |
OLMAOlema Oncology, Inc. | 10K | ±0% | $86.4K | 0.1% |